Tamoxifen Tablets
| Product/Composition:- | Tamoxifen Tablets |
|---|---|
| Strength:- | 10mg, 20mg |
| Form:- | Tablets |
| Production Capacity:- | 10 Million Tablet/Month |
| Packaging:- | 10 X 10 Tablets / Box |
| Therapeutic use:- | Anti Cancer |
| Package Insert/Leaflet:- | Available upon request |
What is tamoxifen?
Tamoxifen is the widely used selective estrogen which is a modulator and helps individuals to overcome with the breast cancer.
The medicine was first developed in 1960s by the pharmaceutical company ICI Pharmaceuticals.
In the initial days, studies were made onto the medicine to be as the potential contraceptive.
But later on, the research found out that it has anti-estrogenic properties, which makes it a popular treatment for hormone-sensitive breast cancer.
Later on, in the 1970s, the drug becomes one of the approved doses for breast cancer patients.
No doubt, Tamoxifen has remained to be one of the popular drugs for breast cancer prevention and treatment and upon reducing the reappearance rates and improving survival outcomes.
Moreover, the medicine is widely prescribed for both early and advanced-stage breast cancer and even individuals who are at risk of developing the condition.
Product Overview Table
| Field | Details |
| Product Name | Tamoxifen Tablets |
| INN / Generic Name | Tamoxifen Citrate |
| Therapeutic Class | Selective Estrogen Receptor Modulator (SERM) hormonal antineoplastic |
| Mechanism (brief) | Non-steroidal antiestrogen; competes with estradiol for estrogen receptor binding in target tissue such as breast |
| Indications | ER-positive breast cancer adjuvant and metastatic; male breast cancer; DCIS; risk reduction in high-risk women |
| API Quality | Manufactured using DMF-grade Tamoxifen Citrate |
| Pharmacopoeial Standard | USP / BP / Ph. Eur. / Ph. Int. API monographs exist in all four; finished product to USP |
| Available Strengths | 10 mg and 20 mg tamoxifen base (equivalent to 15.2 mg and 30.4 mg tamoxifen citrate respectively) |
| Dosage Forms | Film-coated or uncoated tablets (30 mg / 40 mg) |
| BCS Classification | Class II low solubility, high permeability (biowaiver not available) |
| Notable Excipient | Contains lactose must be declared in leaflet and dossier |
| Shelf Life | 36 Months |
| Storage | Store below 25°C, protected from light |
| Manufacturing Facility | WHO-GMP certified contained hormonal / antineoplastic block with dedicated AHU |
| Safety Labelling | Boxed warning applies in the risk-reduction and DCIS setting must carry through to leaflet and artwork |
| Dossier Available | Yes CTD / ACTD / eCTD format |
| Regulatory Documents | CoA, CoPP, FSC, MOA, GMP Certificate, Stability Data, BE Study Report, HBEL Assessment |
| Markets Served | Africa, Southeast Asia, LATAM, Middle East, CIS |
Product Variants, Dosage Forms & Strengths
Tamoxifen Tablets 20 mg
The principal strength worldwide, corresponding to the standard once-daily adjuvant and metastatic regimen.
Each tablet contains tamoxifen citrate equivalent to 20 mg of tamoxifen base.
Because adjuvant therapy runs for years rather than weeks, buyers in this category weigh supply continuity and batch-to-batch consistency far more heavily than unit price a mid-course supplier change is a clinical and procurement problem, not just a commercial one.
Tamoxifen Tablets 10 mg
The 10 mg presentation supports divided dosing regimens and dose adjustment, and is specified in a number of national oncology formularies alongside the 20 mg strength.
Each tablet contains tamoxifen citrate equivalent to 10 mg of tamoxifen base.
Institutional buyers frequently tender both strengths together, so quoting them as a pair generally converts better than quoting either alone.
Higher Strengths 30 mg / 40 mg
Available in a limited number of markets under specific national approvals
Confirm both manufacturing capability and target-market approval status before listing
Pharmacopoeial Compliance
USP Tamoxifen Citrate Tablets USP is the most widely requested finished-product specification for export
BP and Ph. Eur. tamoxifen citrate monographs are established in both, supporting Commonwealth and European-referencing markets
Ph. Int. (International Pharmacopoeia) a tamoxifen citrate monograph exists, which matters where WHO or UN agency procurement routes apply
Assay, dissolution, uniformity of dosage units, related substances and isomeric purity are tested against the declared monograph.
Isomeric purity deserves particular attention: tamoxifen citrate is the trans-isomer of a triphenylethylene derivative, and control of the corresponding isomer is a specification point reviewers examine closely.
Regulatory & Dossier Support
Dossier Availability
CTD (Common Technical Document): ICH-aligned, for regulated and semi-regulated markets
ACTD (ASEAN Common Technical Dossier): Philippines, Vietnam, Myanmar, Indonesia, Cambodia
eCTD: for authorities mandating electronic submission
Module 3 quality documentation including process validation, content uniformity, dissolution method validation, isomeric purity control and impurity profiling against the USP related substances specification
Stability data real-time and accelerated under ICH Zone IVb (30°C / 75% RH), plus photostability data supporting the light-protection storage statement
Country-specific dossier customisation and regulatory query response support included
Bioequivalence No Biowaiver Available
Tamoxifen is a BCS Class II molecule poorly soluble and highly permeable so dissolution is the rate-limiting step for absorption and BCS-based biowaivers, which apply only to Class I substances, are not available.
In-vivo bioequivalence (BE) data against the innovator comparator is required for market authorisation in effectively every jurisdiction. Our submissions carry BE study reports, together with a discriminatory dissolution method validated to detect formulation differences that matter clinically.
BE study report available Strength-to-strength biowaiver may be accepted between 10 mg and 20 mg where proportional similarity and comparable dissolution profiles are demonstrated subject to the individual authority
Study population: BE for this molecule is conducted under the applicable national guidance; where local ethics rules restrict healthy-volunteer exposure to antineoplastic agents, a patient-based design may be required
Note for buyers: tamoxifen is converted to its more active metabolite endoxifen by CYP2D6, which is polymorphic.
This does not change the BE requirement, but it does mean analytical method and study design details receive closer scrutiny than for a simple parent-drug product.
Drug Master File
Drug Master File (DMF) reference for the Tamoxifen Citrate API available for cross-referencing in your registration dossier
API sourced against a qualified vendor with full impurity, isomeric purity, residual solvent and particle-size characterisation
CDSCO / Indian DMF reference accepted by a large number of importing authorities shortens query cycles
Manufacturing Compliance
WHO-GMP certified manufacturing facility, audit-ready, with inspection reports shared on an NDA basis.
Site Master File (SMF) available for regulatory submissions.
Manufactured in a contained hormonal / antineoplastic block segregated from general oral solid production, with dedicated air handling units, pressure cascade and airlocks.
This is not an optional enhancement; a potent hormonal antineoplastic manufactured in shared general facilities is a finding waiting to happen.
Operator protection controls documented: tamoxifen is a reproductive toxicant and containment is an occupational health requirement as much as a product-quality one.
Validated cleaning with swab and rinse recovery data, and analytical methods sensitive enough to demonstrate residues below the calculated acceptance limit.
Compliant with the requirements of NAFDAC (Nigeria), PPB (Kenya), FDA Philippines, DRAP (Pakistan) and INVIMA (Colombia).
Complete Documentation Package (Per Shipment)
| Document | Purpose |
| Certificate of Analysis (CoA) | Confirms batch quality against the agreed specification |
| Certificate of Pharmaceutical Product (CoPP / CPP) | Required for MOH registration in most importing countries |
| Free Sale Certificate (FSC) | Confirms the product is freely sold in the country of manufacture |
| Method of Analysis (MOA) | Analytical methodology mandatory dossier component |
| GMP Certificate | Confirms manufacturing site compliance, including the contained block |
| Stability Data | Real-time and accelerated ICH Zone IVb, plus photostability |
| BE Study Report | In-vivo bioequivalence against innovator comparator not waivable for this molecule |
| Dissolution Profile Report | Discriminatory method; the key performance parameter for a Class II drug |
| Isomeric Purity Data | Trans-isomer control a specification point reviewers examine closely |
| HBEL / PDE Assessment | Toxicologist-authored exposure limit underpinning cleaning acceptance criteria |
| Cleaning Validation Summary | Swab and rinse recovery against the HBEL-derived limit |
| Excipient Declarations | For all inactive ingredients, including the lactose declaration |
| Batch Manufacturing Records (BMR) | Available on request, NDA basis |
Cross-Contamination Control & Health-Based Exposure Limits
A health-based exposure limit (HBEL): expressed as a Permitted Daily Exposure is established for tamoxifen by a qualified toxicologist and forms the scientific basis for our cleaning acceptance criteria
Cleaning validation is demonstrated against that limit, not against an arbitrary generic default, with analytical methods sensitive enough to detect residues at the required level
Where regulatory expectations require dedicated facilities for highly potent or genotoxic compounds, our containment arrangement and its qualification are documented in the Site Master File (SMF) and available for review
Cross-contamination risk assessment covers shared corridors, personnel and equipment flows, dust containment and waste handling not only equipment cleaning
Buyers are encouraged to request the containment section of the SMF during technical evaluation; we share it on an NDA basis rather than asking you to take it on trust
Clinical Indications & Therapeutic Information
Tamoxifen citrate is a non-steroidal antiestrogen and a selective estrogen receptor modulator (SERM).
It competes with estradiol for estrogen receptor binding sites in target tissue such as breast, which is the basis of its use in hormone-receptor-positive disease.
Tamoxifen is included on the WHO Model List of Essential Medicines, which secures its place in national essential medicines lists and recurring government oncology procurement
Principal indications: adjuvant treatment of ER-positive breast cancer, metastatic breast cancer in women and men, ductal carcinoma in situ following surgery and radiation, and reduction of breast cancer incidence in women at high risk
A boxed warning applies in the risk-reduction and DCIS settings, covering serious and life-threatening events including uterine malignancies, stroke and pulmonary embolism.
This warning must carry through in full to the leaflet and artwork for every market abbreviating it is a regulatory breach, not an editorial choice.
Tamoxifen is a prodrug converted by CYP2D6 to endoxifen, its more active metabolite. CYP2D6 is polymorphic, and concomitant strong CYP2D6 inhibitors are managed clinically prescriber territory, noted here only because it shapes the drug-interaction section of the leaflet.
Contraindicated in pregnancy; effective contraception requirements and pregnancy warnings are part of reference labelling and must appear in local artwork
Demand structure: adjuvant therapy typically runs for five years or longer per patient, which makes tamoxifen a long-horizon, forecastable line item for oncology procurement rather than an episodic purchase but also one where supply interruption has direct clinical consequences
Export Packaging & Supply Chain
Primary Packaging Options
| Presentation | Packaging Options |
| Tamoxifen Tablets 20 mg | Alu-Alu blister 10×10 and 3×10; HDPE bottle of 30 / 60 tablets with induction seal |
| Tamoxifen Tablets 10 mg | Alu-Alu blister 10×10; HDPE bottle of 30 / 60 tablets |
| Hospital / Tender Supply | Bulk cartons with hospital-pack overprinting and unit-dose blister options |
| Higher strengths | Confirm pack configuration only if these SKUs are approved and manufactured |
Tamoxifen is light sensitive, so both blister and bottle presentations are specified with light protection, and photostability data supports the storage statement.
Because adjuvant courses run for years, pack size selection has a real adherence dimension 30-count bottles map cleanly to monthly dispensing, while blisters suit programme distribution where tamper evidence and unit traceability matter more.
Why Source Tamoxifen Tablets From Us?
Contained Hormonal Manufacturing: Produced in a segregated contained antineoplastic block with dedicated air handling, pressure cascade and validated containment. GMP certificate and Site Master File (SMF) shared on request.
HBEL-Based Cleaning Validation: Toxicologist-authored exposure limits underpin our cleaning acceptance criteria, with analytical methods sensitive enough to prove compliance. This is the documentation oncology buyers request first.
In-Vivo Bioequivalence Data Held: Tamoxifen cannot be registered on a biowaiver. We hold BE study reports against innovator comparator, removing the most common cause of dossier rejection for this molecule.
Complete Dossier for 100+ Countries: CTD, ACTD and eCTD dossiers pre-compiled, with regulatory query response support included.
WHO Essential Medicine Molecule: Tamoxifen’s WHO Model List of Essential Medicines status keeps it inside national EMLs and recurring oncology tenders, supporting multi-year volume forecasting.
Supply Continuity for Long-Course Therapy: Adjuvant treatment runs for years. We plan contained-block campaigns against committed forecasts so that continuity is engineered rather than hoped for.
Frequently Asked Questions
Q1. Do you provide a dossier for Tamoxifen Tablets?
Yes. We provide complete dossiers in CTD, ACTD and eCTD formats for Tamoxifen Citrate Tablets 10 mg and 20 mg.
The dossier includes Module 3 quality documentation, process validation, ICH Zone IVb stability and photostability data, dissolution method validation, isomeric purity control and the bioequivalence study report.
Country-specific customisation and regulatory query support are included as standard.
Q2. Is your Tamoxifen manufactured in a contained facility?
Yes. Tamoxifen is produced in a segregated contained hormonal and antineoplastic block with dedicated air handling units, pressure cascade and airlocks, physically separated from general oral solid production.
Containment qualification, operator protection controls and the cross-contamination risk assessment are documented in our Site Master File (SMF), which we share on an NDA basis during technical evaluation.
Q3. Can Tamoxifen Tablets be registered on a biowaiver instead of a BE study?
No. Tamoxifen is a BCS Class II molecule poorly soluble, highly permeable and BCS-based biowaivers apply only to Class I substances. In-vivo bioequivalence data against innovator comparator is required in effectively every jurisdiction.
A strength-to-strength waiver between 10 mg and 20 mg may be accepted where proportional similarity and comparable dissolution are demonstrated, subject to the authority.
Q4. What cleaning validation evidence do you provide for a potent product?
We provide a toxicologist-authored health-based exposure limit (HBEL) assessment expressed as a Permitted Daily Exposure, and cleaning validation demonstrated against that limit using analytical methods sensitive enough to detect residues at the required level.
Swab and rinse recovery data, along with the cleaning validation summary, are available for review.
Q5. Which pharmacopoeial standard do your Tamoxifen Tablets comply with?
Our tablets are manufactured to Tamoxifen Citrate Tablets USP specification, the standard most widely requested for export.
Tamoxifen citrate monographs also exist in BP, Ph. Eur. and Ph. Int. Please confirm your market requirement at enquiry stage so the correct specification is fixed before batch allocation.
Q6. Can you supply Tamoxifen Tablets under our private label?
Yes, with one firm limit. We offer private label manufacturing across both strengths, handling blister and carton artwork and multi-lingual labelling.
However, safety labelling including the boxed warning where applicable, the pregnancy contraindication and the lactose declaration is fixed regulatory content and cannot be reduced or omitted for design reasons.
Q7. What is the MOQ and lead time for Tamoxifen Tablets?
MOQ varies by strength, pack configuration and artwork requirement. Because production runs in scheduled campaigns within a contained block, lead time is driven by campaign planning rather than line availability alone.
Please contact our export team with your target market, required strengths and annual forecast for MOQ, lead time and a tailored quotation.
Q8. Which countries do you export Tamoxifen finished formulations to?
We export across Africa (Nigeria, Kenya, Ghana, Egypt, Tanzania), Southeast Asia (Philippines, Vietnam, Cambodia, Indonesia), Latin America (Colombia, Peru, Ecuador) and the Middle East and CIS (Iraq, Jordan, Uzbekistan, Kazakhstan).
Our regulatory team provides country-specific registration support for each market.
Ready to Source Tamoxifen Tablets FDF?
Share your target market, required strengths and annual forecast, and our export team will respond with the applicable specification, dossier format, pack options, campaign lead time and pricing.
If you are conducting technical evaluation, request the dossier summary, BE study abstract, containment section of the SMF and a sample CoA no commitment required.





